Exelon Patch and Combination With Memantine Comparative Trial
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the tolerability between rivastigmine patch monotherapy
and combination therapy with memantine in patients with Alzheimer's disease (AD). The
secondary objective is to compare the efficacy and safety between rivastigmine patch
monotherapy and combination therapy with memantine in patients with AD. The study hypothesis
is that the tolerability of the combination therapy with memantine is not inferior to that of
rivastigmine patch monotherapy in AD patients.